The association between tumour heterogeneity and immune evasion mechanisms in hepatocellular carcinoma and its clinical implications

Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related mortality worldwide. The emergence of combination therapy, atezolizumab (anti-PDL1, immune checkpoint inhibitor) and bevacizumab (anti-VEGF) has revolutionised the management of HCC. Despite this breakthrough, the best overa...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	British journal of cancer 2024-08, Vol.131 (3), p.420-429
Hauptverfasser:	Chen, Kaina, Shuen, Timothy W. H., Chow, Pierce K. H.
Format:	Artikel
Sprache:	eng
Schlagworte:	631/67/1504/1610/4029 631/67/327 Bevacizumab Biomedical and Life Sciences Biomedicine Cancer Research Carcinoma, Hepatocellular - drug therapy Carcinoma, Hepatocellular - immunology Carcinoma, Hepatocellular - pathology Drug Resistance Epidemiology Hepatocellular carcinoma Humans Immune checkpoint inhibitors Immune Checkpoint Inhibitors - therapeutic use Immune Evasion Liver cancer Liver Neoplasms - drug therapy Liver Neoplasms - immunology Liver Neoplasms - pathology Molecular Medicine Oncology Review Review Article Tumor Escape Tumor microenvironment Tumor Microenvironment - immunology Tumors Vascular endothelial growth factor
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!